BioPharmSignal logoBioPharmSignal

Biotech News

Pulse Biosciences Schedules Second Quarter 2026 Financial Results Conference Call for August 6, 2026

Pulse Biosciences (PLSE)Pulse BiosciencesEarnings

HAYWARD, Calif. --(BUSINESS WIRE)--Jul. 21, 2026-- Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-PFA or nsPFA™) technology, today announced it will report business updates and financial results for the second quarter

Related news

PLSEPulse Biosciences2026-08-06 20:05 EST

Pulse Biosciences Reports Business Updates and Second Quarter 2026 Financial Results

NEPHNephros2026-08-05 20:00 EST

Nephros Schedules Second Quarter 2026 Financial Results Conference Call

XAIRBeyond Air2026-08-04 12:00 EST

Beyond Air Schedules Conference Call to Discuss Financial Results for the Quarter Ended June 30, 2026

CVRXCVRx2026-07-23 20:30 EST

CVRx to Report Second Quarter 2026 Financial and Operating Results and Host Conference Call on August 6, 2026

AORTArtivion2026-07-23 20:10 EST

Artivion Announces Release Date and Teleconference Call Details for Second Quarter 2026 Financial Results

ICUSeaStar Medical2026-08-06 12:35 EST

SeaStar Medical to Report Second Quarter Financial Results on August 12, 2026

XTNTXtant Medical2026-08-06 12:00 EST

Xtant Medical to Announce Second Quarter 2026 Financial Results on August 11, 2026

AEMDAethlon Medical2026-08-05 12:01 EST

Aethlon Medical to Release First Quarter Financial Results and Host Conference Call on August 13, 2026

IRIXIRIDEX2026-08-04 20:05 EST

Iridex to Report Second Quarter 2026 Financial Results on August 18, 2026

STIMNeuronetics2026-07-28 12:30 EST

Neuronetics to Report Second Quarter 2026 Financial and Operating Results and Host Conference Call

View all latest news

Pulse Biosciences

Nanosecond Pulsed-Field Ablation Pulse Biosciences develops the nPulse platform, which delivers proprietary nanosecond pulsed-field energy to ablate targeted tissue. The technology is designed to create nonthermal cellular effects and is being evaluated in cardiac and soft-tissue applications. Cardiac Catheter System The nPulse Cardiac...

Recent company news

PLSEPulse Biosciences2026-08-06 20:05 EST

Pulse Biosciences Reports Business Updates and Second Quarter 2026 Financial Results

PLSEPulse Biosciences2026-07-30 20:05 EST

Pulse Biosciences to Present at Canaccord Genuity’s 46th Annual Growth Conference

PLSEPulse Biosciences2026-07-29 11:00 EST

Pulse Biosciences Surpasses Enrollment Midpoint in NANOPULSE-AF IDE Pivotal Study

PLSEPulse Biosciences2026-07-21 20:05 EST

Pulse Biosciences Schedules Second Quarter 2026 Financial Results Conference Call for August 6, 2026

PLSEPulse Biosciences2026-07-15 20:05 EST

Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Stock data

Close
38.24 USD
Market cap
1.68B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States